Healthcare Giant Johnson & Johnson Sets Sights on New Milestones

Johnson & Johnson is demonstrating remarkable momentum on dual fronts. The healthcare conglomerate’s shares are approaching a fresh annual peak, bolstered by promising clinical trial outcomes for a novel psoriasis treatment. The critical question now emerges: can this pharmaceutical leader sustain its upward trajectory?

The positive sentiment surrounding Johnson & Johnson is clearly reflected in recent analyst actions. Several prominent financial institutions have significantly revised their outlooks:

• Bernstein lifted its price target from $172 to $193.
• Wells Fargo upgraded the stock from “Hold” to “Buy,” establishing a $212 target.
• BofA Securities followed suit, raising its projection to $198.

This wave of confidence propelled the share price... Read more...